Dihydropyridines from the First to the Fourth Generation: Better Efficacy and Safety;De la Première à la Quatrième Géné ration de Dihydropyridines: Vers une Meilleure Efficacité et une Meilleure Tolérance

Therapie

Volumn 58, Issue 4, 2003, Pages 333-339

  Aouam, Karim ^a   Berdeaux, Alain ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSERM   (France)

Author keywords

Dihydropyridines; Efficacy; Pharmacodynamics; Pharmacokinetics; Safety

Indexed keywords

AMLODIPINE; BYPRESS; DIHYDROPYRIDINE DERIVATIVE; FELODIPINE; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; NICARDIPINE; NIFEDIPINE; NITRENDIPINE;

BIOAVAILABILITY; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; ONSET AGE; PRIORITY JOURNAL; REDUCTION; REVIEW; SIDE EFFECT;

EID: 0344441892     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2003051     Document Type: Article

References (37)

1. Ferrari R. Major differences among the three classes of calcium antagonists. Eur Heart J 1997; 18 Suppl. A: A56-70
2. Ruzicka M, Leenen FH. Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short-versus long-acting 1,4-dihydropyridines. Am J Hypertens 1996; 9: 86-94
3. De Vries RJ, Dunselman PH, Chin Kon Sung UG, et al. Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure. Heart 1996; 75: 159-64
4. Berdeaux A. Arterial baroreceptor reflex and calcium antagonists. Fund Clin Pharmacol 1989; 3: 65s-70s
5. Leenen FH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992; 69: 639-45
6. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940-53
7. Thadani U, Zellner SR, Glasser S, et al. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine: a new second-generation calcium channel blocker in angina pectoris. Circulation 1991; 84: 2398-408
8. The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56: 400-13
9. Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993; 153: 345-53
10. Berdeaux A, Richard V, Thuillez C, et al. Calcium antagonists and coronary circulation during myocardial ischemia. Prog Clin Pharmacol 1990; 12: 79-90
11. Van Zwieten PA, Hansson L, Epstein M. Slowly acting calcium antagonists and their merits. Blood Press 1997; 6: 78-80
12. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954-61
13. Messerli FH, Grossman E. Pedal edema: not all dihydropyridine calcium antagonists are created equal. Am J Hypertens 2002; 15: 1019-20
14. Messerli FH. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am J Hypertens 2002; 15: 94S-7S
15. Simon A, Levenson J. Clinical use of nifedipine GITS in the treatment of hypertension: an overview. Expert Opin Pharmacother 2003; 4: 95-106
16. Lacourcière Y, Poirier L, Dion D, et al. Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure. Am J Cardiol 1990; 65: 467-72
17. Parmley WW, Nesto RW, Singh B, et al. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina: N-CAP Study Group. J Am Coll Cardiol 1992; 19: 1380-9
18. Koyama Y, Kodama K, Suzuki M, et al. Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens 2002; 15: 927-31
19. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72
20. Faulkner JK, McGibney D, Chasseaud LF, et al. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 1986; 22: 21-5
21. Waeber B, Borges ET, Christeler P, et al. Amlodipine compared to nitrendipine in hypertensive patients: the effects on toleration in relationship to the onset of action. Cardiology 1992; 80: 46-53
22. Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol 1994; 73: 28-33
23. Chahine RA, Feldman RL, Giles TD, et al. Randomized placebo-controlled trial of amlodipine in vasospastic angina: Amlodipine Study 160 Group. J Am Coll Cardiol 1993; 21: 1365-70
24. Elkayam U. Calcium channel blockers in heart failure. Cardiology 1998; 89: 38-46
25. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-14
26. Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J 2000; 139: 503-10
27. Angelico P, Guarneri L, Leonardi A, et al. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999; 51: 709-14
28. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-28
29. Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Opin Investig Drugs 1999; 8: 1043-62
30. Herbette LG, Vecchiarelli M, Sartani A, et al. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance: updated molecular model to rationalize its pharmacokinetic properties. Blood Press 1998; 2: 10-7
31. van Zwieten PA, Pfaffendorf M. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses. J Hypertens 1993; 11: S3-8
32. Acanfora D, Trojano L, Gheorghiade M, et al. A randomized, double-blind comparison of 10 and 20mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9: 444-53
33. Fogari R, Malamani GD, Zoppi A, et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle foot subcutaneous interstitial pressure in hypertensive patients: a double-blind randomized parallel group study. Curr Ther Res 2000; 61: 850-62
34. Leonetti G, Magnani B, Pessina AC, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932-40
35. Feld LG, Van Liew JB, Galaske RG, et al. Selectivity of renal injury and proteinuria in the spontaneously hypertensive rat. Kidney Int 1977; 12: 332-43
36. Sabbatini M, Leonardi A, Testa R, et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-9
37. Bianchi G, Passoni A, Griffini PL. Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol Res 1989; 21: 193-200